Background: The extent of lymph node involvement is the most significant prognostic indicator in resected locoregional colorectal cancer.

Objectives: This study aimed to investigate the prognostic value of total lymph nodes identified and ratio of lymph nodes in resected colorectal cancer.

Patients and Methods: Two hundred seventy-five patients with histologically proven resected locoregional invasive colorectal adenocarcinoma from 2003 to 2011 were included. All patients were treated with standard surgical resection for their colorectal cancer. Patients with incomplete data, or unresectable tumors or distant metastases were excluded from the study. All potential prognostic variables were evaluated for their impact on the local control, disease-free, and overall survival rates.

Results: Of the 275 patients, 162 were men and 113 were women with a median age of 54 (range 23-84) years. The mean total lymph nodes were significantly higher in colon cancer than rectal cancer (11 versus 7.5, P = 0.001). In node positive (stage III) patients, the mean lymph nodes ratio was 0.5 for rectal cancers and 0.37 for colon cancers respectively showing a nonsignificant (P = 0.05) trend toward higher lymph nodes ratio in rectal cancer patients. In univariate analysis, the mean total number of lymph node identified was a prognostic factor for 5-year disease free (P = 0.04) and overall survival (P = 0.02) rates. In node positive patients, lymph nodes ratio was a prognostic factor for 5-year local control (P = 0.04), disease free survival (P = 0.01), and overall survival (P = 0.01) rates. On multivariate analysis, advanced primary tumor stage, rectal primary site and the presence of perineural invasion were independent adverse prognostic factors for overall survival.

Conclusions: Total lymph nodes identified and ratio of lymph nodes are associated with oncological outcomes in patients with colorectal cancer.

Keywords: Colorectal Neoplasms; Colon; Rectum; Lymph Nodes; General Surgery; Prognosis; Survival

1. Background

Colorectal cancer is the fourth most frequently diagnosed cancer and the leading cause of cancer death in Iran (1). Most colorectal cancers tend to present as a locoregional disease (2). Currently, the American Joint Committee on Cancer (AJCC), the tumor node metastasis (TNM) staging system is commonly used for staging colorectal cancer. The presence and extent of regional lymph node involvement has been adopted as an element in the N stage of this staging system (3). The total number of lymph nodes examined can easily affect the N stage evaluation (4). Therefore, a minimum of 9 to 12 lymph nodes examination has been recommended for accurately staging colorectal cancer (5, 6). However, inadequate lymph nodes evaluation is a common problem in colorectal cancer and a high proportion of patients had a limited number of lymph nodes examined (7). According to two recent studies performed in our country, only a third of the patients with colorectal cancer underwent adequate lymph nodes examination (8, 9). These evidences point out that a potential risk of understaging is present in these patients. Some stage III patients with inadequate lymph nodes evaluation may be incorrectly classified as stage I or II (4, 10, 11). N stage is the most important prognostic factor in resected loco-
coregional colorectal cancer (12). Several studies have investigated the association between the number of lymph node identified and overall survival in patients with colorectal cancer (13). Some reports indicate that larger number of harvested lymph nodes is associated with improved 5-year survival rates in patients with negative node (stages I and II) colorectal cancer (4, 14). In addition, some evidences from the literature found an important prognostic role for the lymph nodes ratio (i.e. the ratio of positive lymph nodes to the total number of lymph nodes examined) (11).

2. Objectives
This study aimed to investigate the prognostic value of total lymph nodes identified and ratio of lymph nodes in oncological outcomes (i.e. local control, disease free survival, and overall survival rates) of resected colorectal cancer in Shiraz, Southern Iran.

3. Patients and Methods
3.1. Population Study and Patient Evaluation
In this retrospective study, characteristics, prognostic factors and survival rates of 275 patients with histologically proven resected locoregional invasive colorectal adenocarcinoma were reviewed and analyzed. The patients were treated and followed-up at Namazi Hospital, Shiraz University of Medical Sciences during 2003 and 2011. Patients presenting in situ or metastatic disease, with pathologies other than adenocarcinoma, and with unresectable or inoperable disease were excluded. In addition, patients who achieved complete pathological response following neoadjuvant chemoradiation were excluded. We also excluded those with missing or incomplete medical records or who lacked complete pathological reports. All patients underwent standard curative surgical resection for their colorectal cancer. Colorectal cancers were pathologically restaged according to the 7th edition of the AJCC TNM staging system (3). Preliminary investigation included comprehensive history and physical examination, colonoscopy, abdominal and pelvic ultrasonography and computed tomography (CT) scans and/or pelvic magnetic resonance imaging (MRI) and/or transrectal ultrasonography.

3.2. Neoadjuvant and Adjuvant Therapies
Neoadjuvant or adjuvant chemoradiation included conventional external beam radiotherapy using megavoltage linear accelerator photons. A median dose of 50 (range 45-50.4) Gy external beam radiotherapy was delivered via a daily fraction of 1.8-2 Gy, with five fractions per week. Concurrent chemotherapy consisted of oral capecitabine, 825 mg/m<sup>2</sup> twice daily during the whole period of the radiotherapy with weekend breaks; or intravenous bolus 5-fluorouracil 425 mg/m<sup>2</sup>/day and folinic acid 20 mg/m<sup>2</sup>/day on days one to five of the first and last weeks of radiation. Adjuvant chemotherapy consisted of capecitabine 1000 mg/m<sup>2</sup> twice daily for 14 of every three-week cycles, plus oxaliplatin 130 mg/m<sup>2</sup> intravenously on day 1 (CAPEOX regimen); or 5-fluorouracil 200 mg/m<sup>2</sup> bolus on day 1, followed by bolus 5-FU 400 mg/m<sup>2</sup> and then 5-FU 600 mg/m<sup>2</sup> over 22-hour infusion on days 1 and 2, (FOLFOX regimen). All patients receiving neoadjuvant chemoradiation underwent standard curative surgery with at least 4-6 weeks interval.

3.3. Statistical Analysis
Clinical and pathological variables were analyzed using the SPSS for windows version 17 statistical software (SPSS, Chicago, IL). The lymph nodes ratio was defined as the ratio of positive lymph nodes to the total number of lymph nodes identified. Local control rate was defined as the proportion of patients who were free of locoregional recurrent disease at 5 years. Disease-free survival rate was defined as the percentage of patients free of rectal cancer at 5 years; an overall survival rate was defined as the percentage of patients alive at 5 years. The survival durations were measured from the date of initial treatment till the events of locoregional failure (locoregional control), any type of treatment failure (disease free survival), death from any reason (overall survival) or the last follow-up. All potential tumor and patient characteristics were analyzed for their impact on the local control, disease-free and overall survival rates. Univariate analysis was performed for the local control, disease-free and overall survival rates using the Kaplan Meier method, and prognostic factors were compared using the Log-Rank test. Multiple-covariate analysis was performed using the stepwise hazards regression model for determining any association between total lymph node identified and ratio of lymph node and oncological outcomes. The hazard ratio (HR) for death, with 95% confidence interval (CI) was calculated for the variable groups. The stratified log-rank test was used to compare treatment results in each variable group (rectum versus colon). All P values were 2-tailed, and P < 0.05 was considered statistically significant.

4. Results
4.1. The patients and Tumor Characteristics
Of the 275 patients, 162 were men and 113 were women with a median age of 54 (range 23-84) years. At the time of diagnosis, 181 patients (66%) were node negative and 94 patients (34%) were node positive. The mean total lymph nodes were significantly higher in colon cancer than rectal cancer (11 versus 7.5, P = 0.001). However, there was no statistically significance difference in the mean positive lymph nodes between rectal cancers
and colon cancers. In addition, in node positive (stage III) patients, the mean lymph nodes ratio was 0.5 for rectal cancers and 0.37 for colon cancers respectively, showing a nonsignificant \( (P = 0.052) \) trend toward higher lymph nodes ratio in patients with rectal cancer (Table 1).

### Table 1. The Patient and Tumor Characteristics by Primary Site

| Primary Sites | P value |
|---------------|---------|
| Rectum | Colon | Total |
| **Gender** | | | 0.903<sup>a</sup> |
| Male | 86 | 76 | 162 |
| Female | 61 | 52 | 113 |
| **Age, yr** | | | 0.017<sup>b</sup> |
| mean (SD) | 56.7 (13.7) | 52.8 (12.6) | 54.6 (14.1) |
| **Tumor stage** | | | 0.770<sup>a</sup> |
| T0-1 | 4 | 4 | 8 |
| T2 | 38 | 27 | 65 |
| T3 | 100 | 92 | 192 |
| T4 | 4 | 5 | 9 |
| **Total LN<sup>c</sup> examined** | | | 0.001<sup>b</sup> |
| mean (SD) | 7.5 (7.1) | 11.0 (10.4) | 9.3 (9.1) |
| **Positive LNs** | | | 0.538<sup>b</sup> |
| mean (SD) | 4.0 (3.9) | 3.4 (5.4) | 3.7 (4.7) |
| **LNs ratio in stage III** | | | 0.052<sup>b</sup> |
| mean (SD) | 0.50 (0.3) | 0.37 (0.2) | 0.44 (0.3) |

<sup>a</sup>Pearson Chi-Square  
<sup>b</sup>Independent-samples t-test  
<sup>c</sup>Abbreviation: LN, Lymph Node

### Table 2. Distribution of Treatment Modalities and Primary Sites in 275 Patients With Colorectal Cancer

| Treatment Modalities | Primary Site | Total |
|----------------------|-------------|-------|
| Surgery, followed by concurrent ChTRT<sup>a</sup> and ChT | 82 | 46 | 128 |
| Surgery, followed by sequential RT and ChT | 8 | 1 | 9 |
| Surgery, followed by ChT alone | 8 | 62 | 70 |
| Surgery, followed by RT alone | 3 | 1 | 4 |
| Surgery alone | 4 | 14 | 18 |
| Neoadjuvant ChTRT, followed by surgery, followed by ChT | 22 | 3 | 25 |
| Neoadjuvant RT, followed by surgery, followed by ChT | 7 | 0 | 7 |
| Neoadjuvant ChT, followed by surgery, followed by ChT | 13 | 1 | 14 |
| Total | 147 | 128 | 275 |

<sup>a</sup>Abbreviations: ChT, chemotherapy; ChTRT, chemoradiation; RT, radiotherapy

### 4.2. Treatment Schedules

Table 2 illustrates the distribution of different therapies used for the 275 patients with colorectal cancer. Accordingly, surgical resection followed by adjuvant concurrent chemoradiation followed by chemotherapy (55%) and neoadjuvant concurrent chemoradiation followed by surgical resection followed by chemotherapy (15%) were the most frequent treatment schedules used in patients with rectal cancer. Whereas, patients with colon cancer, surgery followed by adjuvant chemotherapy (48%) and surgery followed by adjuvant concurrent chemoradiation followed by chemotherapy (36%) were the most common treatment schedules used.
4.3. Univariate Analysis of Prognostic Factors

The 5-year local control, disease-free, and overall survival rates for all patients were 78.1%, 62.6%, and 70.5% respectively (Figures 1, 2, and 3). On univariate analysis, primary tumor stage ($P = 0.01$), lymph nodes ratio ($P = 0.04$) (Figure 4), and the presence of perineural invasion ($P < 0.001$) were found as prognostic factors for local control rate. The total lymph nodes identified was not a prognostic factor for local control rate (Figure 5).

We found primary tumor stage ($P = 0.04$), tumor grade ($P = 0.02$), the presence of lymphatic-vascular invasion ($P = 0.001$), the presence of perineural invasion ($P < 0.001$), the total lymph node identified ($P = 0.04$), positive lymph nodes ($P = 0.004$), and lymph nodes ratio ($P = 0.01$) as prognostic factors for disease free survival (Figures 6 and 7). In addition, primary tumor stage ($P = 0.03$), the presence of lymphatic-vascular invasion ($P = 0.009$), the presence of perineural invasion ($P = 0.001$), the total lymph node identified ($P = 0.02$), and lymph nodes ratio ($P = 0.01$) were prognostic factors for overall survival (Table 3).
Figures 8 and 9 illustrate the prognostic impact of total lymph nodes identified and lymph nodes ratio on the 5-year overall survival rates in our patients. On stratified Log-Rank test analysis according to the primary site (rectum versus colon), higher tumor stage (P = 0.01), the presence of lymphatic-vascular invasion (P = 0.006), the presence of perineural invasion (P = 0.009) and lymph nodes ratio more than 0.5 (P = 0.02) were found to have a negative prognostic influence on the overall survival (Table 4).

In subgroup analysis of node negative patients, the total lymph nodes examined was a prognostic factor only for overall survival (P = 0.006); but not for local control (P = 0.10), or disease free survival (P = 0.06). In addition, in subgroup analysis of node positive patients, we found lymph nodes ratio as a prognostic factor for 5-year local control (P = 0.04), disease free survival (P = 0.01), and overall survival (P = 0.01) rates. However, the total examined lymph nodes was not found as a prognostic factor for local control (P = 0.80), disease free survival (P = 0.44), or overall survival (P = 0.95) in this group.

4.4. Multiple Regression Analysis of Prognostic Factors

Prognostic factors that were significant in univariate analysis were assessed using multiple regression analysis. On this analysis, poorly differentiated tumors (HR = 3.868, 95% CI = 1.297-11.532, P = 0.015), and the presence of perineural invasion were independent adverse prognostic factors for local control (HR = 6.355, 95% CI = 2.344-17.230, P < 0.001). Poorly differentiated tumors (HR = 4.613, 95% CI = 1.929-11.031, P = 0.001), the presence of lymphatic-vascular invasion (HR = 3.514, 95% CI = 1.127-10.958, P = 0.03), and perineural invasion (HR = 4.079, 95% CI = 1.991-8.355, P < 0.001), and lymph nodes ratio more than 0.5 (HR = 2.173, 95% CI = 1.100-4.293, P = 0.02) had a negative influence on disease free survival. In addition, Advanced primary tumor stage (HR = 2.625, 95% CI = 1.955-5.766, P = 0.01), rectal primary site (HR = 2.503, 95% CI = 1.142-5.485, P = 0.02), and the presence of perineural invasion (HR = 3.099, 95% CI = 1.98-8.014, P = 0.02) were independent adverse prognostic factors for overall survival.
Table 3. Univariate Analysis of Prognostic Factors for 5-Year Local Control, Disease Free Survival and Overall Survival Rates in 275 Patients With Colorectal Cancer

|                      | Patients, No. | 5-year LC<sup>a</sup> Rate, % | P value<sup>b</sup> | 5-year DFS Rate, % | P value<sup>b</sup> | 5-year OS Rate, % | P value<sup>b</sup> |
|----------------------|---------------|-------------------------------|---------------------|--------------------|---------------------|--------------------|---------------------|
| **Age, y**           |               |                               |                     |                    |                     |                    |                     |
| < 55                 | 143           | 78.9                          | 0.71                | 63.8               | 0.76                | 72.8               | 0.32                |
| ≥ 55                 | 132           | 76.3                          | 0.71                | 60.5               | 0.76                | 66.3               | 0.71                |
| **Sex**              |               |                               |                     |                    |                     |                    |                     |
| Male                 | 162           | 78.0                          | 0.75                | 60.5               | 0.50                | 68.3               | 0.49                |
| Female               | 113           | 78.3                          | 0.75                | 65.8               | 0.50                | 74.2               | 0.49                |
| **Tumor stage**      |               |                               |                     |                    |                     |                    |                     |
| T0-1                 | 8             | 100.0                         | 0.01                | 100.0              | 0.04                | 100.0              | 0.03                |
| T2                   | 65            | 82.4                          | 0.01                | 75.8               | 0.04                | 75.6               | 0.03                |
| T3                   | 192           | 78.0                          | 0.01                | 59.1               | 0.04                | 68.7               | 0.03                |
| T4                   | 9             | 38.1                          | 0.01                | 31.3               | 0.04                | 44.4               | 0.03                |
| **Tumor size, cm**   |               |                               | 0.66                | 0.45               | 0.32                |                     |                     |
| ≤ 5                  | 182           | 77.3                          | 0.66                | 59.4               | 0.45                | 65.7               | 0.32                |
| > 5                  | 93            | 79.4                          | 0.66                | 66.8               | 0.45                | 76.6               | 0.32                |
| **Tumor grade**      |               |                               | 0.08                | 0.02               | 0.22                |                     |                     |
| Well differentiated   | 189           | 79.5                          | 0.08                | 65.3               | 0.02                | 73.3               | 0.22                |
| Moderately differentiated | 66        | 80.1                          | 0.08                | 63.7               | 0.02                | 69.0               | 0.22                |
| Poorly differentiated | 15            | 42.9                          | 0.08                | 33.0               | 0.02                | 50.0               | 0.22                |
| **Lymphatic-vascular invasion** |   |                               | 0.08                | 0.001              | 0.009               |                     |                     |
| Negative             | 136           | 83.4                          | 0.08                | 73.9               | 0.001              | 81.8               | 0.009               |
| Positive             | 109           | 67.4                          | 0.08                | 46.2               | 0.001              | 51.4               | 0.009               |
| Not mentioned        | 30            | 88.0                          | 0.08                | 70.1               | 0.001              | 79.9               | 0.009               |
| **Perineural invasion** |          |                               | < 0.001             | < 0.001            | 0.001               |                     |                     |
| Negative             | 114           | 77.2                          | < 0.001             | 61.4               | < 0.001            | 73.0               | 0.001               |
| Positive             | 49            | 49.0                          | < 0.001             | 29.0               | < 0.001            | 41.3               | 0.001               |
| Not mentioned        | 92            | 89.6                          | < 0.001             | 81.2               | < 0.001            | 84.8               | 0.001               |
| **Ob and/or Per**    |               |                               | 0.12                | 0.19               | 0.19                |                     |                     |
| Negative             | 74            | 68.4                          | 0.12                | 56.9               | 0.19                | 64.6               | 0.19                |
| Positive             | 50            | 86.2                          | 0.12                | 76.0               | 0.19                | 85.5               | 0.19                |
| Not mentioned        | 151           | 80.2                          | 0.12                | 59.2               | 0.19                | 62.5               | 0.19                |
| **Total LN examined**|               |                               | 0.18                | 0.04               | 0.02                |                     |                     |
| ≤ 9 LNs              | 186           | 75.3                          | 0.18                | 55.8               | 0.04                | 63.4               | 0.02                |
| > 9 LN               | 89            | 83.2                          | 0.18                | 74.5               | 0.04                | 85.1               | 0.02                |
| **Positive lymph nodes** |          |                               | 0.61                | 0.004              | 0.39                |                     |                     |
| ≤ 1 positive LNs     | 214           | 77.6                          | 0.61                | 65.9               | 0.004              | 70.4               | 0.39                |
| > 1 positive LNs     | 61            | 80.9                          | 0.61                | 49.2               | 0.004              | 71.7               | 0.39                |
| **Lymph node ratio in stage III** |      |                               | 0.04                | 0.01               | 0.01                |                     |                     |
| ≤ 0.5                | 64            | 87.8                          | 0.04                | 59.6               | 0.01                | 83.9               | 0.01                |
| > 0.5                | 30            | 75.6                          | 0.04                | 47.3               | 0.01                | 55.1               | 0.01                |

<sup>a</sup> Abbreviations: DFS, disease free survival; LCR, local control rate; Ob, obstruction; OS, overall survival; Per, perforation
<sup>b</sup> Log-Rank test
Table 4. Univariate Analysis of Prognostic Factors For 5-Year Overall Survival Rates by Stratification of Primary Site in the 275 Patients With Colorectal Cancer

|                        | Rectum |       |       | Colon |       |       |
|------------------------|--------|-------|-------|-------|-------|-------|
|                        | Patients, No. | 5-year OS | P value | Patients, No. | 5-year OS | P value |
| **Age, y**             |        |       |       |        |       |       |
| < 55                   | 72     | 67.6  | 0.11  | 71     | 80.3  | 0.29  |
| ≥ 55                   | 75     | 45.9  | 0.39  | 57     | 93.9  | 0.39  |
| **Sex**                |        |       |       |        |       |       |
| Male                   | 86     | 55.9  | 0.45  | 76     | 88.9  | 0.89  |
| Female                 | 61     | 68.5  | 0.56  | 52     | 82.0  | 0.56  |
| **Tumor stage**        |        |       |       |        |       |       |
| T0-1                   | 4      | 100.0 | 0.09  | 4      | 100.0 | 0.29  |
| T2                     | 38     | 59.7  | 0.29  | 27     | 100.0 | 0.01  |
| T3                     | 100    | 56.4  | 0.62  | 92     | 83.6  | 0.62  |
| T4                     | 4      | 33.3  | 0.01  | 5      | 50.0  | 0.01  |
| **Tumor size, cm**     |        |       |       |        |       |       |
| ≤ 5                    | 104    | 55.5  | 0.43  | 78     | 85.9  | 0.74  |
| > 5                    | 43     | 68.4  | 0.62  | 50     | 85.0  | 0.62  |
| **Tumor grade**        |        |       |       |        |       |       |
| Well differentiated    | 105    | 63.0  | 0.21  | 84     | 89.6  | 0.18  |
| Moderately differentiated | 36  | 55.1  | 0.56  | 31     | 85.9  | 0.09  |
| Poorly differentiated  | 2      | 66.7  | 0.09  | 12     | 40.0  | 0.09  |
| **Lymphatic-vascular invasion** | 0.008 | 0.58 | 0.006 |
| Negative               | 75     | 76.7  | 0.07  | 61     | 89.1  | 0.009 |
| Positive               | 56     | 35.6  | 0.09  | 53     | 79.1  | 0.09  |
| Not mentioned          | 16     | 66.7  | 0.09  | 14     | 90.0  | 0.09  |
| **Perineural invasion**| 0.06   | 0.07  | 0.009 |
| Negative               | 73     | 64.2  | 0.09  | 61     | 89.1  | 0.09  |
| Positive               | 29     | 37.1  | 0.09  | 20     | 63.0  | 0.09  |
| Not mentioned          | 45     | 79.4  | 0.09  | 47     | 89.4  | 0.09  |
| **Ob and/or Per**      | 0.66   | 0.42  | 0.59  |
| Negative               | 52     | 63.3  | 0.59  | 22     | 68.6  | 0.59  |
| Positive               | 18     | 78.6  | 0.59  | 32     | 89.2  | 0.59  |
| Not mentioned          | 77     | 21.9  | 0.59  | 74     | 90.5  | 0.59  |
| **Total LN examined**  | 0.02   | 0.98  | 0.53  |
| ≤ 9 LN                 | 108    | 49.0  | 0.98  | 78     | 88.6  | 0.53  |
| > 9 LN                 | 39     | 88.0  | 0.53  | 50     | 82.6  | 0.53  |
| **Positive lymph nodes**| 0.94  | 0.372 | 0.45  |
| ≤ 1 positive LNs       | 110    | 59.4  | 0.372 | 104    | 86.3  | 0.45  |
| > 1 positive LNs       | 73     | 67.3  | 0.45  | 24     | 80.8  | 0.45  |
| **Lymph node ratio in stage III** | 0.08 | 0.16 | 0.02 |
| ≤ 0.5                  | 29     | 79.9  | 0.16  | 35     | 88.1  | 0.02  |
| > 0.5                  | 19     | 57.7  | 0.02  | 11     | 53.3  | 0.02  |

---

*a* stratified Log-Rank test

*b* Abbreviations: Ob, obstruction; OS, overall survival; Per, perforation

*b* Log-Rank test
Inadequate lymph nodes examined directly and indirectly influence oncological outcomes in patients with resected colorectal cancer (13). Inadequate lymph nodes examination due to inadequate surgical excision can directly compromise locoregional control and survival in these patients. In addition, inadequate lymph nodes examination can indirectly underestimate node staging, which leads to classification of patients with real stage III colorectal cancer as stage I or II disease incorrectly. Subsequently, some patients with stage III are deprived from optimal treatments (8, 13).

In this retrospective study, we investigated the prognostic value of total lymph nodes identified and ratio of lymph nodes in patients who underwent curative resection for colorectal cancer. Univariate and multivariate analysis of the present study showed that lower total lymph nodes identified and higher ratio of lymph nodes were associated with poorer oncologic outcomes in these patients. In addition, tumor stage was found as a more significant prognostic factor than node stage in our patients with inadequate lymph nodes evaluation and staging.

The correlation between total number of lymph nodes identified and oncological outcome of the colorectal cancer has been extensively evaluated (Table 5) (15 - 32). Some studies found that more lymph nodes examined improves survival for patients with node negative colorectal cancer (15, 18, 20, 23, 24). In a retrospective study, Desolneux et al. investigated prognostic variables in 362 patients with resected node-negative (stages I and II) colorectal cancer. They found inadequate total lymph nodes examined as an independent poor prognostic factor (15). In another study, Lachetta et al. evaluated the association between number of lymph nodes examined and survival in patients with stage IIA disease (T3N0M0). They concluded that patients with stage IIA colorectal cancer with more than or equal to 20 lymph nodes examined show better survival compared to those with fewer lymph nodes examined (18). These evidences were in agreement with the results of our report in which the total lymph nodes identified was a prognostic factor for overall survival. Prognostic value of total lymph nodes identified and ratio of lymph nodes in resected node positive colorectal cancer have been evaluated by several investigators (19, 26 - 35).

Johnson et al. performed a large study on patients who underwent surgery for stage III colon cancer between 1988 and 1997 using the data from the surveillance, epidemiology and end results (SEER) cancer registry (33). They found that the number of negative nodes was a significant independent prognostic factor for patients with stages IIIB and IIIC colon cancer. In a retrospective study, Thomas et al. performed a multivariate analysis to find out independent prognostic factors in 1098 patients, which had undergone colorectal cancer resections. They concluded that the presence of positive lymph nodes may not be an accurate indicator for stage III colorectal cancer; and the evaluation of ratio of lymph nodes is a more important prognostic factor in these patients (35). Various cut-off points were considered for the total examined lymph nodes (range 6-40) and lymph nodes ratio (range 0.07-0.69) by researchers in the literature (13, 36). In the present study and based on the mean total lymph nodes and ratio of the lymph nodes, we chose 9 lymph nodes and 0.5 as a cut-off points for the total examined lymph nodes and ratio of the lymph nodes, respectively.

5. Discussion

Inadequate lymph nodes examined directly and indirectly influence oncological outcomes in patients with resected colorectal cancer (13). Inadequate lymph nodes examination due to inadequate surgical excision can directly compromise locoregional control and survival in these patients. In addition, inadequate lymph nodes examination can indirectly underestimate node staging, which leads to classification of patients with real stage III colorectal cancer as stage I or II disease incorrectly. Subsequently, some patients with stage III are deprived from optimal treatments (8, 13).
Table 5. The Prognostic Value of Total Lymph Nodes Examined and Ratio of Lymph Nodes in Oncologic Outcomes of the Colorectal Cancer in the Literature and the Present Study

| Country         | Patients, No. | Primary Site | Stage | Oncologic Outcome | Prognostic Value |
|-----------------|---------------|--------------|-------|-------------------|------------------|
| Nadoshan (9)    | Iran          | Rectum       | III   | DFS, OS           | +          |
| Desolneux (15)  | Germany       | Colorectal   | I-II  | OS                | -          |
| Ogino (17)      | The USA       | Colorectal   | I-IV  | OS                | +          |
| Iachetta (18)   | Italy         | Colorectal   | IIA   | OS                | -          |
| Shao (19)       | China         | Colorectal   | II-III| OS                | +          |
| Peeples (20)    | The USA       | Colorectal   | II    | OS                | -          |
| Choi (21)       | Hong Kong     | Colorectal   | II    | DFS, OS           | +          |
| Vather (22)     | The New Zealand | Colorectal II-III | OS | +          |
| Tsai (23)       | Taiwan        | Colorectal   | II    | OS                | -          |
| Law (25)        | Canada        | Colon        | II    | DFS, OS           | +          |
| Wong (26)       | China         | Colorectal   | III   | DFS, OS           | -          |
| Elias (27)      | Lebanon       | Colorectal   | III   | DFS, OS           | -          |
| Shimomura (28)  | Japan         | Colorectal   | III   | DFS               | +          |
| Park (29)       | Korea         | Colorectal   | III   | OS                | -          |
| Tsikitis (30)   | The USA       | Colon        | III   | DFS, OS           | -          |
| Lee (31)        | Korea         | Rectum       | III   | DFS, OS           | -          |
| Klos (32)       | Netherlands   | Rectum       | II-III| OS                | -          |
| Johnson (33)    | The USA       | Colon        | III   | DSS               | +          |
| Lu (34)         | Taiwan        | Colorectal   | III   | DFS, OS           | -          |
| Ren (37)        | China         | Colorectal   | III   | DFS               | -          |
| Present study   | Iran          | Colorectal   | I-III | DFS, OS           | +          |

Abbreviations: DFS, disease free survival; DSS, disease-specific survival; LN, lymph node; OS, overall survival; TLNE, total lymph node examined

In Iran, Nadoshan et al. investigated the prognostic value of lymph node ratios in selected patients with node positive rectal cancer treated with neoadjuvant chemoradiation. They chose 12 lymph nodes and 0.2 as cut-off points for the total examined lymph nodes and ratio of the lymph nodes, respectively. The results of their study indicated that the total lymph nodes identified and ratio of lymph nodes were important prognostic factors for disease free and overall survival in patients with stage III rectal cancer (9). In accordance with the literature, in our study and by analysis of subgroup patients with stage III, we found lymph node ratio as a prognostic factor for local control, disease free survival, and overall survival in 94 patients with node positive colorectal cancer; however, the total identified lymph nodes was not a prognostic factor for local control, disease free survival, or overall survival. Moreover, compared to the report of Nadoshan et al, our study included a larger population and covered both patients with colon and rectal cancer. The total lymph nodes identified and ratio of lymph nodes are associated with oncological outcomes in patients with colorectal cancer. Tumor stage may be a more useful prognostic indicator than node stage in patients with inadequate lymph nodes staging.

Acknowledgements

The authors would like to thank the Research Improvement Center of Shiraz University of Medical Sciences, Shiraz, IR Iran and Ms. A. Keivanshekouh for improving the use of English in the manuscript.

Authors’ Contribution

Leila Ghahramani: Involved in design, writing and revising the manuscript, and approval of the final version. Leila Moadshoar: Involved in conception, design, data collection, literature review, writing the manuscript, and approval of the final version. Sayed Hasan Hamedi: Involved in conception, design, data collection, literature review and writing the manuscript, and approval of the final version. Samira Razzaghi: Involved in analysis, and interpretation, writing, and revising the manuscript.
and approval of the final manuscript. Mohammad Moh-
hammadianpanah: Involved in design and data collect-
ion, and in literature review, writing, and revising the
manuscript, and approval of the final version.

Financial Disclosure
None of the authors have any conflict of interest, fi-
nancial or otherwise.

Funding/Support
This study was supported by the Colorectal Research
Center, Shiraz University of Medical Sciences as the re-
search number project 90-5680.

References
1. Moradi A, Khayamzadeh M, Guya M, Mirzaei HR, Salmanian R, Rakhsa
a A, et al. Survival of colorectal cancer in Iran. Asian Pac J Clin
Pathol. 2009;10(4):583-6.
2. Moghimi-Dekhordi B, Sabaei A, Zali MR. Prognostic factors in 1,138
Iranian colorectal cancer patients. Int J Colorectal Dis. 2008;23(7):683-8.
3. Greene FL. AJCC Cancer Staging Manual. 7th ed. New York: Spring-
er-Verlag; 2010.
4. Lee S, Hofmann LJ, Davis KG, Waddell BE. Lymph node evalua-
tion of colon cancer and its association with improved staging
and survival in the Department of Defense Health Care System.
Ann Surg Oncol. 2009;16(11):3080-6.
5. Cianchi F, Palomba A, Boddi V, Messerini L, Pucciani F, Perigli G,
et al. Lymph node recovery from colorectal tumor specimens: recom-
menedation for a minimum number of lymph nodes to be
examined. World J Surg. 2002;26(3):384-9.
6. Shia J, Wang H, Nash GM, Klimstra DS. Lymph node staging
in colorectal cancer: revisiting the benchmark of at least 12
lymph nodes in R0 resection. J Am Coll Surg. 2012;214(3):348-55.
7. Baxter NN, Virgink DJ, Rothenberger DA, Morris AM, Jessu-
run J, Virgink BA. Lymph node evaluation in colorectal can-
cer patients: a population-based study. J Natl Cancer Inst.
2005;97(1):239-25.
8. Ghahramani L, Razzaghi S, Mohammadianpanah M, Pourah-
mad S. Adequacy of Lymph Node Staging in Colorectal Cancer:
Analysis of 250 Patients and Analytical Literature Review. Ann Colorectal Res.
2013;1(3):1-41.
9. Nadoshan JJ, Omrani-pour B, Reiki O, Zendedel K, Alibakhsh S,
Mahmoodzadeh H. Prognostive value of lymph node ratios in
node positive rectal cancer treated with preoperative chemoradio-
therapy. Asian Pac J Cancer Prev. 2013;14(6):3769-72.
10. Pheby DF, Levine DF, Pitcher RW, Shepherd NA. Lymph node
harvests directly influence the staging of colorectal cancer:
evidence from a regional audit. J Clin Pathol. 2004;57(1):43-7.
11. Wang J, Hassett JM, Dayton MT, Kulyalat MN. Lymph node ratio:
role in the staging of node-positive colon cancer. Ann Surg Onc.
2008;15(6):6500-8.
12. Omidvari S, Hamedi SH, Mohammadianpanah M, Razzaghi S,
Mosalaei A, Ahmadloo N, et al. Comparison of abdominoperi-
neal resection and low anterior resection in lower and middle
rectal cancer. J Egypt Natl Canc Inst. 2013;25(3):351-60.
13. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph
node evaluation and survival after curative resection of colon
cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433-41.
14. Rivadulla-Serrano MI, Martinez-Ramos D, Arnegol-Carrasco M,
Esrig-Soto J, Paiva-Granuel GA, Fortea-Sanchis C, et al. Impact of
the total number of harvested lymph nodes after colon can-
cer resections on survival in patients without involved lymph
node. Rev Esp Enferm Dig. 2010;102(5):296-301.
15. Desolneux G, Burtin P, Lermite E, Bergamaschi R, Hamy A, Arn-
aud JP. Prognostic factors in node-negative colorectal cancer: a
retrospective study from a prospective database. Int J Colorectal
Dis. 2010;25(7):829-34.
16. Nir S, Greenberg R, Shacham-Shmueli E, White I, Schneebaum
S, Avital S. Number of retrieved lymph nodes and survival in
node-negative patients undergoing laparoscopic colorectal
surgery for cancer. Tech Coloproctol. 2010;14(2):147-52.
17. Ogino S, Nosko K, Irahara N, Shima K, Baba Y, Kinkner GJ, et
al. Negative lymph node count is associated with survival of
colorectal cancer patients, independent of tumoral molecu-
lar alterations and lymphoctic response. Am J Gastroenterol.
2010;105(2):420-33.
18. Jachetta F, Reggiani Bonetti L, Marcheselli L, Di Gregorio C,
Cirilli C, Morsini S, et al. Lymph node evaluation in stage IIA
colorectal cancer and its impact on patient prognosis: a popu-
lation-based study. Acta Oncol. 2013;52(1):1642-90.
19. Shao XL, Han HQ, He XL, Fu Q, Lv YC, Liu G. Impact of number
of retrieved lymph nodes and lymph node ratio on the prognos-
iac in patients with stage II and III colorectal cancer. Zhonghua
Wei Chang Wu Ke Za Zhi. 2011;43(4):2449-53.
20. Pheebles C, Shellnut J, Wasyvar H, Riggs T, Sacksner J, Predictive
factors affecting survival in stage II colorectal cancer: is lymph
node harvesting relevant? Dis Colon Rectum. 2010;53(7):1571-2.
21. Choi HK, Law WL, Poon JT. The optimal number of lymph nodes
examined in stage II colorectal cancer and its impact of on out-
comes. BMC Cancer. 2010;10:267.
22. Vather R, Sammour T, Kokhekar A, Connolly AB, Hill AG. Lymph
node evaluation and long-term survival in stage II and Stage III
colon cancer: a national study. Ann Surg Oncol. 2009;16(3):585-93.
23. Peeples C, Shellnut J, Wasyvar H, Riggs T, Sacksner J, Predictive
factors affecting survival in stage II colorectal cancer: is lymph
node harvesting relevant? Dis Colon Rectum. 2010;53(7):1571-2.
24. Salhi I, Bader G, Jusco D, Salveini C, Mauro DD, Mazaee A,
et al. Number of lymph nodes examined and prognosis of TNM
stage II colorectal cancer. Eur J Cancer. 2005;41(22):272-9.
25. Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna SS, Khal-
li M, et al. Impact of lymph node retrieval and pathological
ultra-staging on the prognosis of stage II colon cancer. J Surg
Oncol. 2003;84(3):320-6.
26. Wong KP, Poon JT, Fan JK, Law WL. Prognostic value of lymph
node ratio in stage III colorectal cancer. Colorectal Dis. 2011;13(10):1166-22.
27. Etias E, Mukherji D, Faraj W, Khalife M, Dimassi H, Eloubeidi M,
et al. Lymph node ratio is an independent prognostic factor in
patients with stage III colorectal cancer: a retrospective study
from the Middle East. World J Oncol. 2012;10:63.
28. Shimomura M, Ikeda S, Takakura Y, Kagawa Y, Tokunaga M, Egi
H, et al. Adequate lymph node examination is essential to
ensure the prognostic value of the lymph node ratio in patients
with stage III colorectal cancer. Surg Today. 2011;41(10):1370-9.
29. Park YH, Lee JI, Park JK, Jo HJ, Kang WK, An CH. Clinical Signifi-
cance of Lymph Node Ratio in Stage III Colon Cancer. J Ko-
rean Soc Coloproctol. 2011;27(5):2605-7.
30. Tsikitis VL, Larson DL, Wolff BG, Kennedy G, Diehl N, Qin R,
et al. Survival in stage III colon cancer is independent of the
total number of lymph nodes retrieved. J Am Coll Surg. 2009;
208(1):42-7.
31. Lee SD, Kim TH, Kim DY, Baek JY, Kim SY, Chang HJ, et al. Lymph
node ratio is an independent prognostic factor in patients
with rectal cancer treated with preoperative chemoradiother-
apy and curative resection. Eur J Surg Oncol. 2012;38(6):478-83.
32. Klos CL, Bordeianou LG, Sylla P, Chang Y, Berger DL. The
prognostic value of lymph node ratio after neoadjuvant
chemoradiotherapy and rectal cancer surgery. Dis Colon Rectum.
2011;54(2):177-9.
33. Johnson PM, Porter GA, Ricciardi R, Baxter NN. Increasing nega-
tive lymph node count is independently associated with im-
proved long-term survival in stage IIIb and IIIC colon cancer.
34. Lu YJ, Lin PC, Lin CC, Wang HS, Yang SH, Jiang JK, et al. The impact of the lymph node ratio is greater than traditional lymph node status in stage III colorectal cancer patients. *World J Surg.* 2013;37(8):1927–33.

35. Thomas M, Biswas S, Mohamed F, Chandrakumaran K, Jha M, Wilson R. Dukes C colorectal cancer: is the metastatic lymph node ratio important? *Int J Colorectal Dis.* 2012;27(3):309–17.

36. Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review. *Ann Surg Oncol.* 2010;17(11):2847–55.

37. Ren JQ, Liu JW, Chen ZZ, Liu SJ, Huang SJ, Huang Y, et al. Prognostic value of the lymph node ratio in stage III colorectal cancer. *Chin J Cancer.* 2012;31(5):241–7.